SCHEDULE: Forian Inc. to Go Private in $2.17 Per Share Cash Merger

A consortium led by Max Wygod has entered into a definitive agreement to acquire Forian Inc. via a tender offer and subsequent merger at $2.17 per share in cash.

Summary

• A consortium of existing shareholders, including Max Wygod and Emily Bushnell, entered into a definitive Merger Agreement on April 2, 2026.
• The transaction is structured as a tender offer for all outstanding shares of Forian Inc. at a price of $2.17 per share in cash.
• The consortium members collectively hold 20,689,142 shares, representing approximately 66.3% of the 31,208,751 total shares outstanding.
• A $5.5 million equity commitment has been provided by the Sponsor to fund the closing payments and transaction costs.
• Following the successful completion of the tender offer, Bravo Merger Sub, Inc. will merge with and into Forian Inc., with Forian surviving as a private, wholly-owned subsidiary of 2025 Acquisition Company, LLC.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive event for shareholders as it provides a guaranteed cash exit in a micro-cap stock that may otherwise lack significant trading liquidity.

Positives

• Provides immediate liquidity to shareholders at a fixed cash price of $2.17 per share.
• The consortium already controls a significant majority (66.3%) of the voting power, which greatly increases the certainty of the deal closing.
• The transaction is backed by a firm $5.5 million equity commitment from the Wygod Family Revocable Trust.
• The merger will be executed under Section 3-106.1 of the Maryland General Corporation Law, which allows for a streamlined closing without a stockholder vote after the tender offer.

Negatives

• The go-private transaction eliminates any future upside potential for public shareholders in the company's growth.
• Consortium members are subject to strict transfer restrictions, preventing them from selling or hedging their shares until the deal is finalized or terminated.
• The offer price is fixed and does not include interest, regardless of the time taken to close.

Risks

• The merger is subject to a minimum tender condition requiring that the buyer group owns at least 50% plus one share of all outstanding stock upon completion of the offer.
• The agreement includes a 'Company Material Adverse Effect' clause that could allow the buyer to terminate the deal if the company's business significantly deteriorates.
• Consummation is contingent upon the non-issuance of any legal injunctions or orders from governmental bodies preventing the merger.

Future Outlook

Upon completion of the merger, Forian Inc. will cease to be a publicly traded company and will operate as a private subsidiary of 2025 Acquisition Company, LLC. The company's shares will be delisted from public exchanges.

Management Comments

• The Special Committee of the Board shall have control of any and all actions to enforce the company's rights as a third-party beneficiary.
• Consortium members have agreed not to participate in legal proceedings challenging the validity of the merger or the board's conduct in connection with the transaction.

Industry Context

StockSavvy.ai notes that this go-private transaction follows a trend where micro-cap healthcare technology and data firms seek private ownership to avoid the costs and regulatory burdens of public markets, especially when the market valuation does not align with management's strategic vision.

Comparison to Industry Standards

• The $2.17 per share price represents a definitive valuation floor set by the company's founders and largest stakeholders.
• The use of a two-step merger (tender offer followed by a back-end merger) is a standard and efficient mechanism for taking Maryland-incorporated companies private.
• The 66.3% pre-existing control by the consortium is significantly higher than typical hostile or third-party takeovers, making a competing bid highly improbable.

Corporate Governance

Legal Proceedings

• Consortium members have agreed to waive their rights to sue the company or the board regarding the validity of the merger or breaches of fiduciary duty related to the transaction.

Related Party Transactions

• The merger is a 'going-private' transaction led by the company's founder, Max Wygod, and other significant existing shareholders.

Stakeholder Impact

• Public shareholders will receive $2.17 per share in cash and lose their equity interest in the company.
• The company will transition from a public reporting entity to a private subsidiary.
• Consortium members will consolidate 100% ownership of the surviving entity.

Next Steps

• Commencement of the formal tender offer by Bravo Merger Sub, Inc.
• Filing of Schedule TO and Schedule 13E-3 by the buyer group with the SEC.
• Filing of Schedule 14D-9 by Forian Inc. containing the Board's recommendation.
• Closing of the merger following the expiration of the tender offer period.

Key Dates

Recommendation

With the consortium controlling 66.3% of the shares, the deal is highly likely to proceed at the stated price. Shareholders should hold their positions to participate in the $2.17 per share cash tender offer, as a superior competing bid is unlikely given the group's majority control.

Keywords

Forian Inc., Max Wygod, Merger Agreement, Tender Offer, Go-Private, Schedule 13D, Healthcare Data, Acquisition, Cash Merger